CANbridge Pharmaceuticals Inc. (1228.HK)

HKD 0.14

(-8.05%)

Long Term Debt Summary of CANbridge Pharmaceuticals Inc.

  • CANbridge Pharmaceuticals Inc.'s latest annual long term debt in 2023 was 107.2 Million CNY , down -7.09% from previous year.
  • CANbridge Pharmaceuticals Inc.'s latest quarterly long term debt in 2024 Q1 was 15.5 Million CNY , up 133.96% from previous quarter.
  • CANbridge Pharmaceuticals Inc. reported annual long term debt of 115.38 Million CNY in 2022, up 764.24% from previous year.
  • CANbridge Pharmaceuticals Inc. reported annual long term debt of 13.35 Million CNY in 2021, down -29.96% from previous year.
  • CANbridge Pharmaceuticals Inc. reported quarterly long term debt of 15.5 Million CNY for 2024 Q2, down 0.0% from previous quarter.
  • CANbridge Pharmaceuticals Inc. reported quarterly long term debt of 115.13 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual Long Term Debt Chart of CANbridge Pharmaceuticals Inc. (2023 - 2019)

Historical Annual Long Term Debt of CANbridge Pharmaceuticals Inc. (2023 - 2019)

Year Long Term Debt Long Term Debt Growth
2023 107.2 Million CNY -7.09%
2022 115.38 Million CNY 764.24%
2021 13.35 Million CNY -29.96%
2020 19.06 Million CNY -66.98%
2019 57.73 Million CNY 0.0%

Peer Long Term Debt Comparison of CANbridge Pharmaceuticals Inc.

Name Long Term Debt Long Term Debt Difference
Uni-Bio Science Group Limited 30.61 Million HKD -250.206%
CK Life Sciences Int'l., (Holdings) Inc. 4.27 Billion HKD 97.491%